Immunis.AI — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Immunis.AI is an early-stage diagnostics company founded in 2019, utilizing artificial intelligence to decode immune and other biological signatures for precision medicine applications. The company's core value proposition lies in its proprietary AI/ML platform that processes multi-omics data to identify novel biomarkers and develop advanced diagnostic tests. Operating in the high-growth digital health and AI-driven diagnostics sector, Immunis.AI targets significant unmet needs in complex disease areas, though it remains in a pre-revenue, platform-development stage. Its success will hinge on validating its technology, securing strategic partnerships, and navigating a competitive and regulated landscape.

Diagnostics

Technology Platform

Proprietary AI/ML platform for analyzing multi-omics data to discover biomarkers and develop diagnostic tests.

Opportunities

The growing demand for AI-powered precision diagnostics presents a massive market opportunity, particularly in oncology and immunology.

The shift towards liquid biopsies and minimally invasive testing creates a favorable environment for novel blood-based diagnostic platforms.

Risk Factors

High technical risk associated with validating AI models for clinical use, significant regulatory hurdles for diagnostic approval, and intense competition from both startups and established diagnostic giants.

Competitive Landscape

Immunis.AI competes in the crowded AI-for-healthcare sector, facing competition from pure-play AI diagnostic firms (e.g., Freenome, Grail), large diagnostic companies building internal AI capabilities, and tech giants (e.g., Google Health) with vast data and computational resources.

More companies in Diagnostics & Precision Medicine →More companies in United States →